New York, NY (May 21)—Pfizer's (
http://www.pfizer.com/) Global R&D president John LaMattina will retire from Pfizer by the end of this year, after 30 years with the company. Pfizer
has begun a search both inside and outside the company for his successor, and Dr. LaMattina will remain during this period
to ensure a smooth transition, according to the company. Chief Financial Officer Alan Levin has resigned after 20 years with
Marlborough, MA (May 15)—Adrian Adams was named president and chief operating officer of Sepracor Inc. (
http://www.sepracor.com/). Adams joined the company in March 2007 after serving as president and chief executive officer of Kos Pharmaceuticals, Inc.
Nutley, NJ (May 14)—Roche's (
http://www.rocheusa.com/) current global head of pharma development operations, Dan Zabrowski, PhD, was promoted to global head of Roche pharma partnering.
Zabrowski will oversee the company's strategic alliances with biotech companies and will create new alliances. He joined the
company in 1995, after holding a variety of positions in regulatory affairs with Syntex, Inc.
Foster City, CA (May 10)—Gilead Sciences, Inc. (
http://www.gilead.com/) promoted Paul Carter to senior vice-president of international commercial operations. Carter joined the company in 2006
as leader of Gilead's European commercial organization. He previously held various positions at GlaxoSmithKline.
South San Francisco, CA (May 9)—Poniard Pharmaceuticals, Inc. (
http://www.poniard.com/) named Ronald A. Martell president and chief operating officer. Martell joins the company after serving as senior vice-president
of commercial operations at ImClone Systems Incorporated.
Quebec, QC, Canada (May 7)—Aeterna Zentaris Inc. (
http://www.aeternazentaris.com/) named Nicholas J. Pelliccione, PhD, senior vice-president of regulatory affairs and quality assurance. Pelliccione joins
the company from Chugai Pharma USA, where he was senior vice-president of regulatory and pharmaceutical sciences. Pelliccione
also spent more than 15 years at Schering Plough Corporation.
Minneapolis, MN (May 4)—Paddock Laboratories, Inc. (
http://www.paddocklabs.com/) appointed Michael Graves president and chief executive officer. Graves joins the company after serving as president of the
generic product division at Par Pharmaceutical Companies, Inc.
Marlborough, MA (May 4)—Joseph Zakrzewski was appointed chief executive officer of Xcellerex, Inc. (
http://www.xcellerex.com/). He joins the company after serving as chief operating officer of Reliant Pharmaceuticals.
Danbury, CT (May 2)—Penwest Pharmaceuticals Co. (
http://www.penw.com/) named Amale Hawi, PhD, senior vice-president of pharmaceutical development. In this capacity, Hawi will manage the pharmaceutics
and pharmacokinetics groups and will be responsible for preclinical and CMC drug-development strategy. Hawi founded A. Hawi
Consulting, Ltd. in 2002 and served as president of the company. She also held various positions at Boehringer Ingelheim Pharmaceuticals.
Boston, MA (May 1)—Solace Pharmaceuticals (
http://www.solacepharma.com/) named Eliot Forster chief executive officer. Forster joins the company after serving as Pfizer's head of development for
Europe and Asia.
Minneapolis, MN (May 1)—Richard A. Krzyzek, PhD, was promoted to vice-president of research for Techne Corporation's (
http://www.techne-corp.com/) biotechnology division. Krzyzek joined R&D Systems, Inc., a subsidiary of Techne, in 1992. He also spent 12 years with Molecular
London, ON, Canada (May 1)—Viron Therapeutics Inc. (
http://www.vironinc.com/) appointed Claude R. Benedict senior vice-president, clinical development and regulatory affairs. Benedict previously served
as senior vice-president and head of development at Archemix Corporation and as senior vice-president of global lead optimization,
drug innovation, and approval for Aventis Pharmaceuticals.